Decoy Therapeutics (NASDAQ:DCOY) Trading Up 4.3% – Still a Buy?

Decoy Therapeutics (NASDAQ:DCOY)’s stock price was up 4.3% on Tuesday . The stock traded as high as $3.71 and last traded at $3.67. 26,566 shares traded hands during trading, a decline of 69% from the average daily volume of 85,117 shares. The stock had previously closed at $3.52.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Decoy Therapeutics has a consensus rating of “Hold” and an average price target of $30.00.

Decoy Therapeutics Price Performance

The firm’s 50-day moving average price is $5.38 and its 200 day moving average price is $6.49. The firm has a market cap of $2.17 million, a P/E ratio of -0.12 and a beta of 0.64.

Decoy Therapeutics (NASDAQ:DCOY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($4.46) earnings per share for the quarter. The firm had revenue of $0.23 million during the quarter. Analysts forecast that Decoy Therapeutics will post -12.97 earnings per share for the current year.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.